Mounjaro on the NHS: Eligibility, Cost & How to Get It in the UK (2026)

Overview

Mounjaro is the brand name for tirzepatide in the United Kingdom and is approved by the MHRA (Medicines and Healthcare products Regulatory Agency) for chronic weight management. In 2023, NICE issued Technology Appraisal TA1026 recommending Mounjaro for use in England through specialist NHS weight management services, marking a significant expansion of NHS obesity treatment options. Access on the NHS is not automatic — patients must meet specific eligibility criteria and be referred into a specialist Tier 3 weight management programme. Outside of NHS pathways, Mounjaro is also available through private clinics and online prescribing services, typically at a cost of £150 to £250 per month depending on dose. This guide explains who qualifies for NHS Mounjaro, how to get a referral, what the NHS Tier 3 pathway involves, how costs compare between NHS and private routes, and what the current landscape looks like in 2026 as the drug continues to roll out across England, Wales, and Scotland.

NICE TA1026: What It Means for NHS Access

NICE Technology Appraisal TA1026, published in 2023, recommended tirzepatide (Mounjaro) for use within the NHS for adults with obesity. This guidance covers England and sets the framework under which the NHS can commission and fund Mounjaro prescriptions. The appraisal concluded that Mounjaro was clinically effective and cost-effective when used as part of a specialist weight management programme alongside dietary advice, physical activity guidance, and behavioural support. Importantly, NICE guidance restricts NHS Mounjaro to specialist services — it is not prescribed by GPs in primary care. Patients must be referred to a Tier 3 (specialist) weight management service. Tier 3 services are multidisciplinary, meaning care involves dietitians, psychologists, physicians, and other specialists working together. The TA also stipulates a maximum treatment duration of 2 years before reassessment, and requires demonstration of meaningful weight loss (at least 5% at 3 months, rising to 10% at 6 months) to continue treatment.

• NICE TA1026 approved tirzepatide (Mounjaro) for NHS use in 2023
• Restricted to specialist Tier 3 weight management services — not available from GPs
• Must be used alongside dietary, physical activity, and behavioural support
• Treatment is time-limited: up to 2 years with mandatory reassessment
• Patients must achieve 5% weight loss by 3 months and 10% by 6 months to continue

NHS Eligibility Criteria for Mounjaro

To qualify for Mounjaro through the NHS in England, patients must meet all of the following criteria set out in NICE TA1026. First, patients must have a BMI of 35 kg/m² or above (or 30 kg/m² or above for those from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds, where lower BMI thresholds apply due to higher metabolic risk). Second, patients must have at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease. Third, patients must be enrolled in a specialist Tier 3 weight management service. Patients who have previously tried other anti-obesity medications without adequate response may be prioritised, though this varies by NHS trust and integrated care board (ICB). In Wales and Scotland, separate guidance applies. The Scottish Medicines Consortium (SMC) and All Wales Medicines Strategy Group (AWMSG) issue their own recommendations, and availability may vary. Patients in those nations should check with their local health board for current access criteria.

• BMI ≥35 kg/m² (or ≥30 kg/m² for South Asian, Black African, and other high-risk ethnic groups)
• At least one weight-related comorbidity (T2D, hypertension, sleep apnoea, CVD, dyslipidaemia)
• Must be referred to and enrolled in a Tier 3 specialist weight management service
• Criteria may vary slightly between integrated care boards (ICBs)
• Wales and Scotland have separate national guidance — check with your local health board

How to Get Mounjaro on the NHS: Step-by-Step

Getting Mounjaro through the NHS involves several steps. First, you will need to see your GP to discuss your weight and any related health conditions. If you meet the BMI and comorbidity thresholds, your GP can refer you to a Tier 3 weight management service. Waiting times for Tier 3 services vary significantly across England — in some areas they can be several months. Once enrolled in Tier 3, the service's multidisciplinary team will assess whether Mounjaro is appropriate for you and, if so, will prescribe and initiate treatment. During treatment, you will have regular check-ins with the Tier 3 team to monitor progress. If you do not achieve the required weight loss milestones (5% at 3 months, 10% at 6 months), the team will reassess whether to continue. If you do respond well, treatment can continue for up to 2 years. After 2 years, reassessment will determine the next steps.

• Step 1: See your GP and discuss your BMI and weight-related health conditions
• Step 2: Request referral to a Tier 3 specialist weight management service
• Step 3: Wait for Tier 3 appointment (can be several months in some areas)
• Step 4: Tier 3 team assesses suitability and initiates Mounjaro if appropriate
• Step 5: Regular monitoring — must hit 5% weight loss at 3 months, 10% at 6 months to continue
• Step 6: Treatment can continue up to 2 years before mandatory reassessment

NHS vs Private: Cost Comparison

On the NHS, Mounjaro is free at the point of use — patients pay only the standard NHS prescription charge (currently £9.90 per item in England in 2026) or nothing if they are exempt (e.g., receiving certain benefits, over 60, or with certain conditions). The NHS bears the full drug cost, which at list price is considerable. In the private sector, Mounjaro costs between £150 and £250 per month depending on the dose. Lower doses (2.5 mg, 5 mg) tend to be at the lower end of this range, while higher maintenance doses (10 mg, 15 mg) are at the higher end. Private providers include high-street pharmacies such as Boots and LloydsPharmacy (via online services), as well as online prescribing platforms such as Juniper, Manual, and others. A private GP or obesity specialist consultation is also typically required before a prescription is issued, adding a further one-off or ongoing cost of £50–150.

• NHS cost to patient: standard prescription charge (~£9.90 per item) or free if exempt
• Private cost: £150–250/month depending on dose
• Starter dose (2.5 mg): typically ~£150–170/month privately
• Maintenance dose (10–15 mg): typically ~£200–250/month privately
• Private consultation: additional £50–150 one-off or per review
• Major private providers: Boots, Juniper, Manual, LloydsPharmacy Online Doctor

Mounjaro Dose Titration: What to Expect

Mounjaro is injected subcutaneously (under the skin) once per week using a pre-filled auto-injector pen. In UK clinical practice, the standard titration schedule begins at 2.5 mg per week for the first 4 weeks. The dose is then increased by 2.5 mg every 4 weeks, as tolerated, until the target maintenance dose is reached. Most UK prescribers aim for a minimum maintenance dose of 5 mg, with 10 mg and 15 mg being the most effective doses for weight loss based on clinical trial data. Nausea, vomiting, and diarrhoea are the most common side effects, particularly during dose escalation. These typically improve as the body adjusts to each new dose level. UK Tier 3 services generally advise patients to remain at a dose level for longer if side effects are significant, rather than pushing through discomfort. The injection can be given in the abdomen, thigh, or upper arm, and the injection site should be rotated each week.

• Week 1–4: 2.5 mg per week
• Week 5–8: 5 mg per week
• Week 9–12: 7.5 mg per week (if tolerated)
• Week 13–16: 10 mg per week (if tolerated)
• Week 17–20: 12.5 mg per week (if tolerated)
• Week 21+: 15 mg per week (if tolerated) — maximum dose
• Side effects (nausea, diarrhoea) typically peak during escalation and settle at stable dose

Mounjaro Availability Across the UK in 2026

Availability of NHS Mounjaro continues to expand across England in 2026, though access varies between integrated care boards (ICBs). Some ICBs have moved faster than others in commissioning Tier 3 services capable of prescribing Mounjaro. Patients in areas with less developed Tier 3 infrastructure may face longer waits or be directed to services in neighbouring areas. In Scotland, the SMC approved tirzepatide in 2024 and NHS Scotland services are progressively rolling out access. In Wales, the AWMSG issued a positive recommendation and health boards are in the process of commissioning services. In Northern Ireland, HSC (Health and Social Care) guidance aligns broadly with NICE TA1026 criteria, though specific service availability varies by trust. For those who cannot access NHS Mounjaro promptly, private routes remain available across the UK, with most online prescribing services offering nationwide delivery.

References

1. NICE Technology Appraisal TA1026: Tirzepatide for Managing Overweight and Obesity (2023)
2. NHS England: Mounjaro (Tirzepatide) for Weight Management — Commissioning Guidance (2024)
3. MHRA: Mounjaro (Tirzepatide) UK Public Assessment Report (2023)
4. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) (2022) — PubMed